Nyxoah SA announced a default judgment in its favor from the Unified Patent Court against Inspire Medical Systems for patent infringement. This legal victory could lead to enforcement actions by Nyxoah, potentially impacting Inspire's market position and product sales in Europe.
Nyxoah SA has secured a default decision from the Unified Patent Court in Germany, ruling in its favor in a patent infringement case against Inspire Medical Systems. This decision concerns Nyxoah's European Patent 2 760 534, which is likely related to sleep apnea treatment devices, a core product area for both companies. For Nyxoah, this is a significant positive development, potentially strengthening its market position and opening avenues for enforcement, such as injunctions or damages, against Inspire in Europe. Conversely, Inspire Medical Systems faces a material negative impact, as this ruling could restrict its ability to sell infringing products in the European market or force it to pay royalties/damages, affecting its revenue and profitability. Traders should monitor Nyxoah's next steps regarding enforcement and Inspire's response, as this could lead to short-term volatility for both stocks and long-term shifts in market share within the European sleep apnea device market.